These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 7996419

  • 1. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
    Silver PJ, Dundore RL, Bode DC, de Garavilla L, Buchholz RA, van Aller G, Hamel LT, Bacon E, Singh B, Lesher GY.
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
    Harris AL, Lemp BM, Bentley RG, Perrone MH, Hamel LT, Silver PJ.
    J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.
    Silver PJ, Pagani ED, Dundore RL, de Garavilla L, Bode DC, Bacon ER.
    Eur J Pharmacol; 1998 May 22; 349(2-3):263-8. PubMed ID: 9671106
    [Abstract] [Full Text] [Related]

  • 4. Impaired effect of salt loading on nitric oxide-mediated relaxation in aortas from stroke-prone spontaneously hypertensive rats.
    Kagota S, Kubota Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K.
    Clin Exp Pharmacol Physiol; 2007 May 22; 34(1-2):48-54. PubMed ID: 17201735
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of low Km cGMP phosphodiesterases and Ca+(+)-regulated protein kinases and relationship to vasorelaxation by cicletanine.
    Silver PJ, O'Connor B, Cumiskey WR, Van Aller G, Hamel LT, Bentley RG, Pagani ED.
    J Pharmacol Exp Ther; 1991 Apr 22; 257(1):382-91. PubMed ID: 1850474
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED, Dundore RL, Bode DC, Bacon ER, Singh B, Lesher GY, Buchholz RA, Silver PJ.
    J Cardiovasc Pharmacol; 1994 Sep 22; 24(3):403-10. PubMed ID: 7528296
    [Abstract] [Full Text] [Related]

  • 7. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P, Prigent AF, Lagarde M, Nemoz G.
    Mol Pharmacol; 1993 Nov 22; 44(5):1027-35. PubMed ID: 8246905
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
    Delpy E, le Monnier de Gouville AC.
    Br J Pharmacol; 1996 Jul 22; 118(6):1377-84. PubMed ID: 8832060
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
    Klein T, Eltze M, Grebe T, Hatzelmann A, Kömhoff M.
    Cardiovasc Res; 2007 Jul 15; 75(2):390-7. PubMed ID: 17383621
    [Abstract] [Full Text] [Related]

  • 11. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor.
    McMahon EG, Palomo MA, Mehta P, Olins GM.
    J Pharmacol Exp Ther; 1989 Dec 15; 251(3):1000-5. PubMed ID: 2557409
    [Abstract] [Full Text] [Related]

  • 12. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
    Whalin ME, Scammell JG, Strada SJ, Thompson WJ.
    Mol Pharmacol; 1991 Jun 15; 39(6):711-7. PubMed ID: 1646946
    [Abstract] [Full Text] [Related]

  • 13. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.
    Delpy E, Coste H, Gouville AC.
    Br J Pharmacol; 1996 Oct 15; 119(3):471-8. PubMed ID: 8894166
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
    Merkel LA, Rivera LM, Perrone MH, Lappe RW.
    Eur J Pharmacol; 1992 May 27; 216(1):29-35. PubMed ID: 1326438
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y, Chackalamannil S, Czarniecki M, Tsai H, Vaccaro H, Cleven R, Cook J, Fawzi A, Watkins R, Zhang H.
    J Med Chem; 1997 Dec 19; 40(26):4372-7. PubMed ID: 9435906
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP.
    Wang M, Urenjak J, Fedele E, Obrenovitch TP.
    Biochem Pharmacol; 2004 Apr 15; 67(8):1619-27. PubMed ID: 15041479
    [Abstract] [Full Text] [Related]

  • 18. Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition.
    Lo YC, Tsou HH, Lin RJ, Wu DC, Wu BN, Lin YT, Chen IJ.
    Life Sci; 2005 Jan 07; 76(8):931-44. PubMed ID: 15589969
    [Abstract] [Full Text] [Related]

  • 19. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium.
    Nagata K, Marbán E, Lawrence JH, Donahue JK.
    J Mol Cell Cardiol; 2001 Mar 07; 33(3):575-80. PubMed ID: 11181024
    [Abstract] [Full Text] [Related]

  • 20. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
    Moreno L, Losada B, Cogolludo Al, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, Pérez-Vizcaíno F.
    Pediatr Res; 2004 Oct 07; 56(4):563-70. PubMed ID: 15295092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.